Tissue transglutaminase (tTg) is a multifunctional enzyme possessing two catalytic sites. One is a calcium‐dependent reaction that leads to formation of isodipeptide cross‐linkages. The cross‐linkages lead to the formation of a protein scaffold in cells undergoing apoptosis. GTP, a negative regulator for this cross‐linking activity, shifts the enzyme's catalytic activity to G‐protein activity.Human embryonic fibroblast cells (WI‐38) and their simian virus‐transformed counterparts (VA13A) grow adherent in vitro. Quantification of the amount of tTg using a fibronectin binding assay showed that VA13A cells contained 0.04493 ng tTg/uL sample in the supernatant and a non‐detectable amount in the pellet fraction. This amount increased to 8.2622ng tTg/uL sample in the supernatant fraction after the VA13A cells were exposed to sodium butyrate. These results were confirmed by indirect immunofluorescence microscopy, electrophoresis and Western blotting.Sodium butyrate induced apoptosis in VA13A cultures, but had no effect on apoptosis in WI‐38 cultures. Preliminary studies with sodium butyrate alone and in combination with calcium ionophore showed not only an increase in apoptosis but also an increased transglutaminase expression. Additionally, sodium butyrate treatment induced growth arrest in both cell lines and reverted the VA13A cells to a more “normal” morphology. These results taken collectively are indicative of a dual role of sodium butyrate; one involving growth arrest and the other apoptosis.
Read full abstract